

[1-232]

1. McCarty, K.S., D.E. Bredesen, and F.S. Vogel, *Neoplasms of the anterior pituitary*. Neurosurgery, 1978. **3**(1): p. 96-104.
2. Cutler, J.R., D.E. Bredesen, R. Edwards, and R.P. Simon, *Failure of naloxone to reverse vascular neurologic deficits*. Neurology, 1983. **33**(11): p. 1517-8.
3. Raskin, N.H., D. Bredesen, W.K. Ehrenfeld, and R.K. Kerlan, *Periodic confusion caused by congenital extrahepatic portacaval shunt*. Neurology, 1984. **34**(5): p. 666-9.
4. Bredesen, D.E., *Neurology: neurologic manifestations of AIDS*. West J Med, 1985. **142**(1): p. 84.
5. Dix, R.D., D.E. Bredesen, K.S. Erlich, and J. Mills, *Recovery of herpesviruses from cerebrospinal fluid of immunodeficient homosexual men*. Ann Neurol, 1985. **18**(5): p. 611-4.
6. Levy, R.M., D.E. Bredesen, and M.L. Rosenblum, *Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature*. J Neurosurg, 1985. **62**(4): p. 475-95.
7. Parry, G.J. and D.E. Bredesen, *Sensory neuropathy with low-dose pyridoxine*. Neurology, 1985. **35**(10): p. 1466-8.
8. Bredesen, D.E., R.M. Levy, and M.L. Rosenblum, *The neurology of human immunodeficiency virus infection*. Q J Med, 1988. **68**(257): p. 665-77.
9. Levy, R.M. and D.E. Bredesen, *Central nervous system dysfunction in acquired immunodeficiency syndrome*. J Acquir Immune Defic Syndr (1988), 1988. **1**(1): p. 41-64.
10. Levy, R.M., D.E. Bredesen, and M.L. Rosenblum, *Opportunistic central nervous system pathology in patients with AIDS*. Ann Neurol, 1988. **23 Suppl**: p. S7-12.
11. Rosenblum, M.L., R.M. Levy, and D.E. Bredesen, *Neurosurgical implications of the acquired immunodeficiency syndrome (AIDS)*. Clin Neurosurg, 1988. **34**: p. 419-45.
12. Rosenblum, M.L., R.M. Levy, D.E. Bredesen, Y.T. So, W. Wara, and J.L. Ziegler, *Primary central nervous system lymphomas in patients with AIDS*. Ann Neurol, 1988. **23 Suppl**: p. S13-6.
13. Scott, M.R., D.A. Butler, D.E. Bredesen, M. Walchli, K.K. Hsiao, and S.B. Prusiner, *Prion protein gene expression in cultured cells*. Protein Eng, 1988. **2**(1): p. 69-76.
14. Engstrom, J.W., D.H. Lowenstein, and D.E. Bredesen, *Cerebral infarctions and transient neurologic deficits associated with acquired immunodeficiency syndrome*. Am J Med, 1989. **86**(5): p. 528-32.
15. Ho, D.D., D.E. Bredesen, H.V. Vinters, and E.S. Daar, *The acquired immunodeficiency syndrome (AIDS) dementia complex*. Ann Intern Med, 1989. **111**(5): p. 400-10.
16. Levy, R.M. and D.E. Bredesen, *Controversies in HIV-related central nervous system disease: neuropsychological aspects of HIV-1 infection*. AIDS Clin Rev, 1989: p. 151-91.
17. Levy, R.M., D.E. Bredesen, M.L. Rosenblum, and R.L. Davis, *Central nervous system disorders in AIDS*. Immunol Ser, 1989. **44**: p. 371-401.
18. Bredesen, D.E., K. Hisanaga, and F.R. Sharp, *Neural transplantation using temperature-sensitive immortalized neural cells: a preliminary report*. Ann Neurol, 1990. **27**(2): p. 205-7.
19. Kahn, J.O., L.D. Kaplan, J.G. Gambertoglio, D. Bredesen, C.J. Arri, L. Turin, T. Kibort, R.L. Williams, J.D. Lifson, and P.A. Volberding, *The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study*. AIDS, 1990. **4**(12): p. 1197-204.
20. Levy, R.M., D.E. Bredesen, and M.L. Rosenblum, *Neurologic complications of HIV infection*. Am Fam Physician, 1990. **41**(2): p. 517-36.
21. Levy, R.M., C.M. Mills, J.P. Posin, S.G. Moore, M.L. Rosenblum, and D.E. Bredesen, *The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study*. J Acquir Immune Defic Syndr (1988), 1990. **3**(5): p. 461-71.

22. Bredesen, D.E., D.J. Kane, D.M. Holtzman, and C.J. Epstein, *Preliminary characterization of long-term reaggregating cultures of trisomy 16 central nervous system*. Prog Clin Biol Res, 1992. **379**: p. 259-70.
23. Yang, J., M. Seelig, S. Rayner, and D.E. Bredesen, *Increasing the proliferative capacity of muscular dystrophy myoblasts*. Muscle Nerve, 1992. **15**(8): p. 941-8.
24. Foster, L.M., T. Phan, A.N. Verity, D. Bredesen, and A.T. Campagnoni, *Generation and analysis of normal and shiverer temperature-sensitive immortalized cell lines exhibiting phenotypic characteristics of oligodendrocytes at several stages of differentiation*. Dev Neurosci, 1993. **15**(2): p. 100-9.
25. Garcia, P.A., D.E. Bredesen, H.V. Vinters, R. Graefin von Einsiedel, R.L. Williams, J.O. Kahn, V.S. Byers, A.S. Levin, L.A. Waites, and R.O. Messing, *Neurological reactions in HIV-infected patients treated with trichosanthin*. Neuropathol Appl Neurobiol, 1993. **19**(5): p. 402-5.
26. Kane, D.J., T.A. Sarafian, R. Anton, H. Hahn, E.B. Gralla, J.S. Valentine, T. Ord, and D.E. Bredesen, *Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species*. Science, 1993. **262**(5137): p. 1274-7.
27. Mah, S.P., L.T. Zhong, Y. Liu, A. Roghani, R.H. Edwards, and D.E. Bredesen, *The protooncogene bcl-2 inhibits apoptosis in PC12 cells*. J Neurochem, 1993. **60**(3): p. 1183-6.
28. Rabizadeh, S., D.J. LaCount, P.D. Friesen, and D.E. Bredesen, *Expression of the baculovirus p35 gene inhibits mammalian neural cell death*. J Neurochem, 1993. **61**(6): p. 2318-21.
29. Rabizadeh, S., J. Oh, L.T. Zhong, J. Yang, C.M. Bitler, L.L. Butcher, and D.E. Bredesen, *Induction of apoptosis by the low-affinity NGF receptor*. Science, 1993. **261**(5119): p. 345-8.
30. Verity, A.N., D. Bredesen, C. Vonderscher, V.W. Handley, and A.T. Campagnoni, *Expression of myelin protein genes and other myelin components in an oligodendrocytic cell line conditionally immortalized with a temperature-sensitive retrovirus*. J Neurochem, 1993. **60**(2): p. 577-87.
31. Zhong, L.T., D.J. Kane, and D.E. Bredesen, *BCL-2 blocks glutamate toxicity in neural cell lines*. Brain Res Mol Brain Res, 1993. **19**(4): p. 353-5.
32. Zhong, L.T., T. Sarafian, D.J. Kane, A.C. Charles, S.P. Mah, R.H. Edwards, and D.E. Bredesen, *bcl-2 inhibits death of central neural cells induced by multiple agents*. Proc Natl Acad Sci U S A, 1993. **90**(10): p. 4533-7.
33. Rabizadeh, S., C.M. Bitler, L.L. Butcher, and D.E. Bredesen, *Expression of the low-affinity nerve growth factor receptor enhances beta-amyloid peptide toxicity*. Proc Natl Acad Sci U S A, 1994. **91**(22): p. 10703-6.
34. Rabizadeh, S. and D.E. Bredesen, *Is p75NGFR involved in developmental neural cell death?* Dev Neurosci, 1994. **16**(3-4): p. 207-11.
35. Sarafian, T.A. and D.E. Bredesen, *Is apoptosis mediated by reactive oxygen species?* Free Radic Res, 1994. **21**(1): p. 1-8.
36. Sarafian, T.A., L. Vartavarian, D.J. Kane, D.E. Bredesen, and M.A. Verity, *bcl-2 expression decreases methyl mercury-induced free-radical generation and cell killing in a neural cell line*. Toxicol Lett, 1994. **74**(2): p. 149-55.
37. Anton, R., J.H. Kordower, D.J. Kane, C.H. Markham, and D.E. Bredesen, *Neural transplantation of cells expressing the anti-apoptotic gene bcl-2*. Cell Transplant, 1995. **4**(1): p. 49-54.
38. Bredesen, D.E., *Neural apoptosis*. Ann Neurol, 1995. **38**(6): p. 839-51.
39. Hisanaga, K., S. Kure, D.E. Bredesen, Y. Ikeda, S. Kohsaka, and F.R. Sharp, *Apoptotic cell death of a temperature-sensitive central neuronal cell line*. Brain Res, 1995. **684**(1): p. 79-86.
40. Kane, D.J., T. Ord, R. Anton, and D.E. Bredesen, *Expression of bcl-2 inhibits necrotic neural cell death*. J Neurosci Res, 1995. **40**(2): p. 269-75.
41. Myers, K.M., G. Fiskum, Y. Liu, S.J. Simmens, D.E. Bredesen, and A.N. Murphy, *Bcl-2 protects neural cells from cyanide/aglycemia-induced lipid oxidation, mitochondrial injury, and loss of viability*. J Neurochem, 1995. **65**(6): p. 2432-40.

42. Rabizadeh, S., E.B. Gralla, D.R. Borchelt, R. Gwinn, J.S. Valentine, S. Sisodia, P. Wong, M. Lee, H. Hahn, and D.E. Bredesen, *Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells*. Proc Natl Acad Sci U S A, 1995. **92**(7): p. 3024-8.
43. Verity, M.A., D.E. Bredesen, and T. Sarafian, *Role of reactive oxygen species (ROS) in neuronal degeneration. Modulation by protooncogene expression*. Ann N Y Acad Sci, 1995. **765**: p. 340.
44. Bredesen, D.E., *Genetic control of neural cell apoptosis*. Perspect Dev Neurobiol, 1996. **3**(2): p. 101-9.
45. Bredesen, D.E., M. Wiedau-Pazos, J.J. Goto, S. Rabizadeh, J.A. Roe, E.B. Gralla, L.M. Ellerby, and J.S. Valentine, *Cell death mechanisms in ALS*. Neurology, 1996. **47**(4 Suppl 2): p. S36-8; discussion S38-9.
46. Ellerby, L.M., H.M. Ellerby, S.M. Park, A.L. Holleran, A.N. Murphy, G. Fiskum, D.J. Kane, M.P. Testa, C. Kayalar, and D.E. Bredesen, *Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2*. J Neurochem, 1996. **67**(3): p. 1259-67.
47. Kayalar, C., T. Ord, M.P. Testa, L.T. Zhong, and D.E. Bredesen, *Cleavage of actin by interleukin 1 beta-converting enzyme to reverse DNase I inhibition*. Proc Natl Acad Sci U S A, 1996. **93**(5): p. 2234-8.
48. Lyons, T.J., H. Liu, J.J. Goto, A. Nersissian, J.A. Roe, J.A. Graden, C. Cafe, L.M. Ellerby, D.E. Bredesen, E.B. Gralla, and J.S. Valentine, *Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein*. Proc Natl Acad Sci U S A, 1996. **93**(22): p. 12240-4.
49. Murphy, A.N., D.E. Bredesen, G. Cortopassi, E. Wang, and G. Fiskum, *Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria*. Proc Natl Acad Sci U S A, 1996. **93**(18): p. 9893-8.
50. Sarafian, T.A., D.E. Bredesen, and M.A. Verity, *Cellular resistance to methylmercury*. Neurotoxicology, 1996. **17**(1): p. 27-36.
51. Srinivasan, A., L.M. Foster, M.P. Testa, T. Ord, R.W. Keane, D.E. Bredesen, and C. Kayalar, *Bcl-2 expression in neural cells blocks activation of ICE/CED-3 family proteases during apoptosis*. J Neurosci, 1996. **16**(18): p. 5654-60.
52. Wiedau-Pazos, M., J.J. Goto, S. Rabizadeh, E.B. Gralla, J.A. Roe, M.K. Lee, J.S. Valentine, and D.E. Bredesen, *Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis*. Science, 1996. **271**(5248): p. 515-8.
53. Wiedau-Pazos, M., J.R. Trudell, C. Altenbach, D.J. Kane, W.L. Hubbell, and D.E. Bredesen, *Expression of bcl-2 inhibits cellular radical generation*. Free Radic Res, 1996. **24**(3): p. 205-12.
54. Bredesen, D.E., L.M. Ellerby, P.J. Hart, M. Wiedau-Pazos, and J.S. Valentine, *Do posttranslational modifications of CuZnSOD lead to sporadic amyotrophic lateral sclerosis?* Ann Neurol, 1997. **42**(2): p. 135-7.
55. Bredesen, D.E. and S. Rabizadeh, *p75NTR and apoptosis: Trk-dependent and Trk-independent effects*. Trends Neurosci, 1997. **20**(7): p. 287-90.
56. Ellerby, H.M., S.J. Martin, L.M. Ellerby, S.S. Naiem, S. Rabizadeh, G.S. Salvesen, C.A. Casiano, N.R. Cashman, D.R. Green, and D.E. Bredesen, *Establishment of a cell-free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases*. J Neurosci, 1997. **17**(16): p. 6165-78.
57. Hileman, M.R., B.S. Chapman, S. Rabizadeh, V.V. Krishnan, D. Bredesen, N. Assa-Munt, and L.A. Plesniak, *A cytoplasmic peptide of the neurotrophin receptor p75NTR: induction of apoptosis and NMR determined helical conformation*. FEBS Lett, 1997. **415**(2): p. 145-54.
58. Keane, R.W., A. Srinivasan, L.M. Foster, M.P. Testa, T. Ord, D. Nonner, H.G. Wang, J.C. Reed, D.E. Bredesen, and C. Kayalar, *Activation of CPP32 during apoptosis of neurons and astrocytes*. J Neurosci Res, 1997. **48**(2): p. 168-80.

59. Kruman, I., A.J. Bruce-Keller, D. Bredesen, G. Waeg, and M.P. Mattson, *Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis*. J Neurosci, 1997. **17**(13): p. 5089-100.
60. Longo, V.D., L.M. Ellerby, D.E. Bredesen, J.S. Valentine, and E.B. Gralla, *Human Bcl-2 reverses survival defects in yeast lacking superoxide dismutase and delays death of wild-type yeast*. J Cell Biol, 1997. **137**(7): p. 1581-8.
61. Ruan, Y., S. Rabizadeh, D. Camerini, and D.E. Bredesen, *Expression of CD40 induces neural apoptosis*. J Neurosci Res, 1997. **50**(3): p. 383-90.
62. Yeo, T.T., J. Chua-Couzens, L.L. Butcher, D.E. Bredesen, J.D. Cooper, J.S. Valletta, W.C. Mobley, and F.M. Longo, *Absence of p75NTR causes increased basal forebrain cholinergic neuron size, choline acetyltransferase activity, and target innervation*. J Neurosci, 1997. **17**(20): p. 7594-605.
63. Bredesen, D.E., X. Ye, A. Tasinato, S. Sperandio, J.J. Wang, N. Assa-Munt, and S. Rabizadeh, *p75NTR and the concept of cellular dependence: seeing how the other half die*. Cell Death Differ, 1998. **5**(5): p. 365-71.
64. Bruce-Keller, A.J., J.G. Begley, W. Fu, D.A. Butterfield, D.E. Bredesen, J.B. Hutchins, K. Hensley, and M.P. Mattson, *Bcl-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid beta-peptide*. J Neurochem, 1998. **70**(1): p. 31-9.
65. Jurgensmeier, J.M., Z. Xie, Q. Deveraux, L. Ellerby, D. Bredesen, and J.C. Reed, *Bax directly induces release of cytochrome c from isolated mitochondria*. Proc Natl Acad Sci U S A, 1998. **95**(9): p. 4997-5002.
66. Martindale, D., A. Hackam, A. Wiczorek, L. Ellerby, C. Wellington, K. McCutcheon, R. Singaraja, P. Kazemi-Esfarjani, R. Devon, S.U. Kim, et al., *Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates*. Nat Genet, 1998. **18**(2): p. 150-4.
67. Mehlen, P., S. Rabizadeh, S.J. Snipas, N. Assa-Munt, G.S. Salvesen, and D.E. Bredesen, *The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis*. Nature, 1998. **395**(6704): p. 801-4.
68. Spear, N., A.G. Estevez, G.V. Johnson, D.E. Bredesen, J.A. Thompson, and J.S. Beckman, *Enhancement of peroxynitrite-induced apoptosis in PC12 cells by fibroblast growth factor-1 and nerve growth factor requires p21Ras activation and is suppressed by Bcl-2*. Arch Biochem Biophys, 1998. **356**(1): p. 41-5.
69. Stennicke, H.R., J.M. Jurgensmeier, H. Shin, Q. Deveraux, B.B. Wolf, X. Yang, Q. Zhou, H.M. Ellerby, L.M. Ellerby, D. Bredesen, et al., *Pro-caspase-3 is a major physiologic target of caspase-8*. J Biol Chem, 1998. **273**(42): p. 27084-90.
70. Wei, H., W. Wei, D.E. Bredesen, and D.C. Perry, *Bcl-2 protects against apoptosis in neuronal cell line caused by thapsigargin-induced depletion of intracellular calcium stores*. J Neurochem, 1998. **70**(6): p. 2305-14.
71. Wellington, C.L., L.M. Ellerby, A.S. Hackam, R.L. Margolis, M.A. Trifiro, R. Singaraja, K. McCutcheon, G.S. Salvesen, S.S. Propp, M. Bromm, et al., *Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract*. J Biol Chem, 1998. **273**(15): p. 9158-67.
72. Ellerby, H.M., W. Arap, L.M. Ellerby, R. Kain, R. Andrusiak, G.D. Rio, S. Krajewski, C.R. Lombardo, R. Rao, E. Ruoslahti, et al., *Anti-cancer activity of targeted pro-apoptotic peptides*. Nat Med, 1999. **5**(9): p. 1032-8.
73. Ellerby, L.M., R.L. Andrusiak, C.L. Wellington, A.S. Hackam, S.S. Propp, J.D. Wood, A.H. Sharp, R.L. Margolis, C.A. Ross, G.S. Salvesen, et al., *Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity*. J Biol Chem, 1999. **274**(13): p. 8730-6.

74. Ellerby, L.M., A.S. Hackam, S.S. Propp, H.M. Ellerby, S. Rabizadeh, N.R. Cashman, M.A. Trifiro, L. Pinsky, C.L. Wellington, G.S. Salvesen, et al., *Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity*. J Neurochem, 1999. **72**(1): p. 185-95.
75. Hong, C.S., L. Caromile, Y. Nomata, H. Mori, D.E. Bredesen, and E.H. Koo, *Contrasting role of presenilin-1 and presenilin-2 in neuronal differentiation in vitro*. J Neurosci, 1999. **19**(2): p. 637-43.
76. Irie, S., T. Hachiya, S. Rabizadeh, W. Maruyama, J. Mukai, Y. Li, J.C. Reed, D.E. Bredesen, and T.A. Sato, *Functional interaction of Fas-associated phosphatase-1 (FAP-1) with p75(NTR) and their effect on NF-kappaB activation*. FEBS Lett, 1999. **460**(2): p. 191-8.
77. Krajewski, S., M. Krajewska, L.M. Ellerby, K. Welsh, Z. Xie, Q.L. Deveraux, G.S. Salvesen, D.E. Bredesen, R.E. Rosenthal, G. Fiskum, and J.C. Reed, *Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia*. Proc Natl Acad Sci U S A, 1999. **96**(10): p. 5752-7.
78. Rabizadeh, S., S. Rabizadeh, X. Ye, J.J. Wang, and D.E. Bredesen, *Neurotrophin dependence mediated by p75NTR: contrast between rescue by BDNF and NGF*. Cell Death Differ, 1999. **6**(12): p. 1222-7.
79. Ye, X., P. Mehlen, S. Rabizadeh, T. VanArsdale, H. Zhang, H. Shin, J.J. Wang, E. Leo, J. Zapata, C.A. Hauser, et al., *TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction*. J Biol Chem, 1999. **274**(42): p. 30202-8.
80. Bordeaux, M.C., C. Forcet, L. Granger, V. Corset, C. Bidaud, M. Billaud, D.E. Bredesen, P. Edery, and P. Mehlen, *The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease*. EMBO J, 2000. **19**(15): p. 4056-63.
81. Bredesen, D.E., *Apoptosis: overview and signal transduction pathways*. J Neurotrauma, 2000. **17**(10): p. 801-10.
82. Cafe, C., M.P. Testa, P.J. Sheldon, W.P. French, L.M. Ellerby, and D.E. Bredesen, *Loss of oxidation-reduction specificity in amyotrophic lateral sclerosis-associated CuZnSOD mutants*. J Mol Neurosci, 2000. **15**(2): p. 71-83.
83. Ellerby, L.M. and D.E. Bredesen, *Measurement of cellular oxidation, reactive oxygen species, and antioxidant enzymes during apoptosis*. Methods Enzymol, 2000. **322**: p. 413-21.
84. Kelner, G.S., M. Lee, M.E. Clark, D. Maciejewski, D. McGrath, S. Rabizadeh, T. Lyons, D. Bredesen, P. Jenner, and R.A. Maki, *The copper transport protein Atox1 promotes neuronal survival*. J Biol Chem, 2000. **275**(1): p. 580-4.
85. Kluck, R.M., L.M. Ellerby, H.M. Ellerby, S. Naiem, M.P. Yaffe, E. Margoliash, D. Bredesen, A.G. Mauk, F. Sherman, and D.D. Newmeyer, *Determinants of cytochrome c pro-apoptotic activity. The role of lysine 72 trimethylation*. J Biol Chem, 2000. **275**(21): p. 16127-33.
86. Lu, D.C., S. Rabizadeh, S. Chandra, R.F. Shayya, L.M. Ellerby, X. Ye, G.S. Salvesen, E.H. Koo, and D.E. Bredesen, *A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor*. Nat Med, 2000. **6**(4): p. 397-404.
87. Mehlen, P. and D.E. Bredesen, *[Dependence receptors: links between apoptosis, nervous system development and control of tumorigenesis]*. Bull Cancer, 2000. **87**(7-8): p. 537-41.
88. Rabizadeh, S., X. Ye, S. Sperandio, J.J. Wang, H.M. Ellerby, L.M. Ellerby, C. Giza, R.L. Andrusiak, H. Frankowski, Y. Yaron, et al., *Neurotrophin dependence domain: a domain required for the mediation of apoptosis by the p75 neurotrophin receptor*. J Mol Neurosci, 2000. **15**(3): p. 215-29.
89. Sperandio, S., I. de Belle, and D.E. Bredesen, *An alternative, nonapoptotic form of programmed cell death*. Proc Natl Acad Sci U S A, 2000. **97**(26): p. 14376-81.
90. Wang, J.J., S. Rabizadeh, A. Tasinato, S. Sperandio, X. Ye, M. Green, N. Assa-Munt, D. Spencer, and D.E. Bredesen, *Dimerization-dependent block of the proapoptotic effect of p75(NTR)*. J Neurosci Res, 2000. **60**(5): p. 587-93.

91. Wang, J.J., A. Tasinato, D.W. Ethell, M.P. Testa, and D.E. Bredesen, *Phosphorylation of the common neurotrophin receptor p75 by p38beta2 kinase affects NF-kappaB and AP-1 activities*. J Mol Neurosci, 2000. **15**(1): p. 19-29.
92. Wei, H., P. Leeds, R.W. Chen, W. Wei, Y. Leng, D.E. Bredesen, and D.M. Chuang, *Neuronal apoptosis induced by pharmacological concentrations of 3-hydroxykynurenine: characterization and protection by dantrolene and Bcl-2 overexpression*. J Neurochem, 2000. **75**(1): p. 81-90.
93. Wellington, C.L., R. Singaraja, L. Ellerby, J. Savill, S. Roy, B. Leavitt, E. Cattaneo, A. Hackam, A. Sharp, N. Thornberry, et al., *Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells*. J Biol Chem, 2000. **275**(26): p. 19831-8.
94. Bredesen, D.E., *Neurodegenerative disease and cancer: two sides of a coin?* Hosp Pract (1995), 2001. **36**(9): p. 39-42, 45.
95. del Rio, G., T.F. Bartley, H. del-Rio, R. Rao, K.L. Jin, D.A. Greenberg, M. Eshoo, and D.E. Bredesen, *Mining DNA microarray data using a novel approach based on graph theory*. FEBS Lett, 2001. **509**(2): p. 230-4.
96. del Rio, G., S. Castro-Obregon, R. Rao, H.M. Ellerby, and D.E. Bredesen, *APAP, a sequence-pattern recognition approach identifies substance P as a potential apoptotic peptide*. FEBS Lett, 2001. **494**(3): p. 213-9.
97. Ethell, D.W., E. Bossy-Wetzel, and D.E. Bredesen, *Caspase 7 can cleave tumor necrosis factor receptor-1 (p60) at a non-consensus motif, in vitro*. Biochim Biophys Acta, 2001. **1541**(3): p. 231-8.
98. Forcet, C., X. Ye, L. Granger, V. Corset, H. Shin, D.E. Bredesen, and P. Mehlen, *The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation*. Proc Natl Acad Sci U S A, 2001. **98**(6): p. 3416-21.
99. Gerlag, D.M., E. Borges, P.P. Tak, H.M. Ellerby, D.E. Bredesen, R. Pasqualini, E. Ruoslahti, and G.S. Firestein, *Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature*. Arthritis Res, 2001. **3**(6): p. 357-61.
100. Lee, M., D.H. Hyun, K.A. Marshall, L.M. Ellerby, D.E. Bredesen, P. Jenner, and B. Halliwell, *Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome*. Free Radic Biol Med, 2001. **31**(12): p. 1550-9.
101. Lee, S., T. Furuya, T. Kiyota, N. Takami, K. Murata, Y. Niidome, D.E. Bredesen, H.M. Ellerby, and G. Sugihara, *De novo-designed peptide transforms Golgi-specific lipids into Golgi-like nanotubules*. J Biol Chem, 2001. **276**(44): p. 41224-8.
102. Peel, A.L., R.V. Rao, B.A. Cottrell, M.R. Hayden, L.M. Ellerby, and D.E. Bredesen, *Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue*. Hum Mol Genet, 2001. **10**(15): p. 1531-8.
103. Rao, R.V., E. Hermel, S. Castro-Obregon, G. del Rio, L.M. Ellerby, H.M. Ellerby, and D.E. Bredesen, *Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation*. J Biol Chem, 2001. **276**(36): p. 33869-74.
104. Stoka, V., B. Turk, S.L. Schendel, T.H. Kim, T. Cirman, S.J. Snipas, L.M. Ellerby, D. Bredesen, H. Freeze, M. Abrahamson, et al., *Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route*. J Biol Chem, 2001. **276**(5): p. 3149-57.
105. Zhong, L.T., A. Manzi, E. Skowronski, L. Notterpek, A.L. Fluharty, K.F. Faull, I. Masada, S. Rabizadeh, M. Varsanyi-Nagy, Y. Ruan, et al., *A monoclonal antibody that induces neuronal apoptosis binds a metastasis marker*. Cancer Res, 2001. **61**(15): p. 5741-8.
106. Arap, W., W. Haedicke, M. Bernasconi, R. Kain, D. Rajotte, S. Krajewski, H.M. Ellerby, D.E. Bredesen, R. Pasqualini, and E. Ruoslahti, *Targeting the prostate for destruction through a vascular address*. Proc Natl Acad Sci U S A, 2002. **99**(3): p. 1527-31.
107. Castro-Obregon, S., G. Del Rio, S.F. Chen, R.A. Swanson, H. Frankowski, R.V. Rao, V. Stoka, S. Vesce, D.G. Nicholls, and D.E. Bredesen, *A ligand-receptor pair that triggers a non-apoptotic form of programmed cell death*. Cell Death Differ, 2002. **9**(8): p. 807-17.

108. Frankowski, H., S. Castro-Obregon, G. del Rio, R.V. Rao, and D.E. Bredesen, *PLAIDD, a type II death domain protein that interacts with p75 neurotrophin receptor*. *Neuromolecular Med*, 2002. **1**(3): p. 153-70.
109. Galvan, V., S. Chen, D. Lu, A. Logvinova, P. Goldsmith, E.H. Koo, and D.E. Bredesen, *Caspase cleavage of members of the amyloid precursor family of proteins*. *J Neurochem*, 2002. **82**(2): p. 283-94.
110. Kurakin, A. and D. Bredesen, *Target-assisted iterative screening reveals novel interactors for PSD95, Nedd4, Src, Abl and Crk proteins*. *J Biomol Struct Dyn*, 2002. **19**(6): p. 1015-29.
111. Rao, R.V., S. Castro-Obregon, H. Frankowski, M. Schuler, V. Stoka, G. del Rio, D.E. Bredesen, and H.M. Ellerby, *Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway*. *J Biol Chem*, 2002. **277**(24): p. 21836-42.
112. Rao, R.V., A. Peel, A. Logvinova, G. del Rio, E. Hermel, T. Yokota, P.C. Goldsmith, L.M. Ellerby, H.M. Ellerby, and D.E. Bredesen, *Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78*. *FEBS Lett*, 2002. **514**(2-3): p. 122-8.
113. Wellington, C.L., L.M. Ellerby, C.A. Gutekunst, D. Rogers, S. Warby, R.K. Graham, O. Loubser, J. van Raamsdonk, R. Singaraja, Y.Z. Yang, et al., *Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease*. *J Neurosci*, 2002. **22**(18): p. 7862-72.
114. Ellerby, H.M., S. Lee, L.M. Ellerby, S. Chen, T. Kiyota, G. del Rio, G. Sugihara, Y. Sun, D.E. Bredesen, W. Arap, and R. Pasqualini, *An artificially designed pore-forming protein with anti-tumor effects*. *J Biol Chem*, 2003. **278**(37): p. 35311-6.
115. Galvan, V., A. Logvinova, S. Sperandio, H. Ichijo, and D.E. Bredesen, *Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1)*. *J Biol Chem*, 2003. **278**(15): p. 13325-32.
116. Kurakin, A.V., S. Wu, and D.E. Bredesen, *Atypical recognition consensus of CIN85/SETA/Ruk SH3 domains revealed by target-assisted iterative screening*. *J Biol Chem*, 2003. **278**(36): p. 34102-9.
117. Lu, D.C., G.M. Shaked, E. Masliah, D.E. Bredesen, and E.H. Koo, *Amyloid beta protein toxicity mediated by the formation of amyloid-beta protein precursor complexes*. *Ann Neurol*, 2003. **54**(6): p. 781-9.
118. Lu, D.C., S. Soriano, D.E. Bredesen, and E.H. Koo, *Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity*. *J Neurochem*, 2003. **87**(3): p. 733-41.
119. Mehlen, P. and D.E. Bredesen, *Meeting report: cellular dependence--old concept, new mechanisms*. *Sci STKE*, 2003. **2003**(213): p. pe55.
120. Peel, A.L. and D.E. Bredesen, *Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice*. *Neurobiol Dis*, 2003. **14**(1): p. 52-62.
121. Rabizadeh, S. and D.E. Bredesen, *Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR)*. *Cytokine Growth Factor Rev*, 2003. **14**(3-4): p. 225-39.
122. Bredesen, D.E., *The non-existent aging program: how does it work?* *Aging Cell*, 2004. **3**(5): p. 255-9.
123. Bredesen, D.E., *Rebuttal to Austad: 'Is aging programmed?* *Aging Cell*, 2004. **3**(5): p. 261-2.
124. Bredesen, D.E., *Toward a mechanistic taxonomy of cell death programs*. *J Alzheimers Dis*, 2004. **6**(6 Suppl): p. S3-6.
125. Bredesen, D.E., P. Mehlen, and S. Rabizadeh, *Apoptosis and dependence receptors: a molecular basis for cellular addiction*. *Physiol Rev*, 2004. **84**(2): p. 411-30.
126. Castro-Obregon, S., R.V. Rao, G. del Rio, S.F. Chen, K.S. Poksay, S. Rabizadeh, S. Vesce, X.K. Zhang, R.A. Swanson, and D.E. Bredesen, *Alternative, nonapoptotic programmed cell death: mediation by arrestin 2, ERK2, and Nur77*. *J Biol Chem*, 2004. **279**(17): p. 17543-53.
127. Galvan, V., A.V. Kurakin, and D.E. Bredesen, *Interaction of checkpoint kinase 1 and the X-linked inhibitor of apoptosis during mitosis*. *FEBS Lett*, 2004. **558**(1-3): p. 57-62.
128. Hashimoto, Y., Y. Kaneko, E. Tsukamoto, H. Frankowski, K. Kouyama, Y. Kita, T. Niihura, S. Aiso, D.E. Bredesen, M. Matsuoka, and I. Nishimoto, *Molecular characterization of neurohybrid cell*

- death induced by Alzheimer's amyloid-beta peptides via p75NTR/PLAIDD*. J Neurochem, 2004. **90**(3): p. 549-58.
129. Hermel, E., J. Gafni, S.S. Propp, B.R. Leavitt, C.L. Wellington, J.E. Young, A.S. Hackam, A.V. Logvinova, A.L. Peel, S.F. Chen, et al., *Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease*. Cell Death Differ, 2004. **11**(4): p. 424-38.
  130. Jin, K., V. Galvan, L. Xie, X.O. Mao, O.F. Gorostiza, D.E. Bredesen, and D.A. Greenberg, *Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APP<sup>Sw,Ind</sup>) mice*. Proc Natl Acad Sci U S A, 2004. **101**(36): p. 13363-7.
  131. Kurakin, A., S. Wu, and D.E. Bredesen, *Target-assisted iterative screening of phage surface display cDNA libraries*. Methods Mol Biol, 2004. **264**: p. 47-60.
  132. Mazelin, L., A. Bernet, C. Bonod-Bidaud, L. Pays, S. Arnaud, C. Gespach, D.E. Bredesen, J.Y. Scoazec, and P. Mehlen, *Netrin-1 controls colorectal tumorigenesis by regulating apoptosis*. Nature, 2004. **431**(7004): p. 80-4.
  133. Mehlen, P. and D.E. Bredesen, *The dependence receptor hypothesis*. Apoptosis, 2004. **9**(1): p. 37-49.
  134. Peel, A.L., N. Sorscher, J.Y. Kim, V. Galvan, S. Chen, and D.E. Bredesen, *Tau phosphorylation in Alzheimer's disease: potential involvement of an APP-MAP kinase complex*. Neuromolecular Med, 2004. **5**(3): p. 205-18.
  135. Rao, R.V. and D.E. Bredesen, *Misfolded proteins, endoplasmic reticulum stress and neurodegeneration*. Curr Opin Cell Biol, 2004. **16**(6): p. 653-62.
  136. Rao, R.V., H.M. Ellerby, and D.E. Bredesen, *Coupling endoplasmic reticulum stress to the cell death program*. Cell Death Differ, 2004. **11**(4): p. 372-80.
  137. Rao, R.V., K.S. Poksay, S. Castro-Obregon, B. Schilling, R.H. Row, G. del Rio, B.W. Gibson, H.M. Ellerby, and D.E. Bredesen, *Molecular components of a cell death pathway activated by endoplasmic reticulum stress*. J Biol Chem, 2004. **279**(1): p. 177-87.
  138. Sperandio, S., K. Poksay, I. de Belle, M.J. Lafuente, B. Liu, J. Nasir, and D.E. Bredesen, *Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix*. Cell Death Differ, 2004. **11**(10): p. 1066-75.
  139. Yokota, T., M. Miyagishi, T. Hino, R. Matsumura, A. Tasinato, M. Urushitani, R.V. Rao, R. Takahashi, D.E. Bredesen, K. Taira, and H. Mizusawa, *siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme*. Biochem Biophys Res Commun, 2004. **314**(1): p. 283-91.
  140. Bredesen, D.E., P. Mehlen, and S. Rabizadeh, *Receptors that mediate cellular dependence*. Cell Death Differ, 2005. **12**(8): p. 1031-43.
  141. Cottrell, B.A., V. Galvan, S. Banwait, O. Gorostiza, C.R. Lombardo, T. Williams, B. Schilling, A. Peel, B. Gibson, E.H. Koo, et al., *A pilot proteomic study of amyloid precursor interactors in Alzheimer's disease*. Ann Neurol, 2005. **58**(2): p. 277-89.
  142. Stoka, V., S.F. Chen, V. Turk, and D.E. Bredesen, *Developmental shift in the apoptat: comparison of neurones and astrocytes*. FEBS Lett, 2005. **579**(27): p. 6147-50.
  143. Thibert, B., D.E. Bredesen, and G. del Rio, *Improved prediction of critical residues for protein function based on network and phylogenetic analyses*. BMC Bioinformatics, 2005. **6**: p. 213.
  144. Warner, H., J. Anderson, S. Austad, E. Bergamini, D. Bredesen, R. Butler, B.A. Carnes, B.F. Clark, V. Cristofalo, J. Faulkner, et al., *Science fact and the SENS agenda. What can we reasonably expect from ageing research?* EMBO Rep, 2005. **6**(11): p. 1006-8.
  145. Bredesen, D.E., R.V. Rao, and P. Mehlen, *Cell death in the nervous system*. Nature, 2006. **443**(7113): p. 796-802.
  146. Galvan, V., O.F. Gorostiza, S. Banwait, M. Ataie, A.V. Logvinova, S. Sitaraman, E. Carlson, S.A. Sagi, N. Chevallier, K. Jin, et al., *Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664*. Proc Natl Acad Sci U S A, 2006. **103**(18): p. 7130-5.



147. Rao, R.V., K. Niazi, P. Mollahan, X. Mao, D. Crippen, K.S. Poksay, S. Chen, and D.E. Bredesen, *Coupling endoplasmic reticulum stress to the cell-death program: a novel HSP90-independent role for the small chaperone protein p23*. Cell Death Differ, 2006. **13**(3): p. 415-25.
148. Saganich, M.J., B.E. Schroeder, V. Galvan, D.E. Bredesen, E.H. Koo, and S.F. Heinemann, *Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP*. J Neurosci, 2006. **26**(52): p. 13428-36.
149. Shaked, G.M., M.P. Kummer, D.C. Lu, V. Galvan, D.E. Bredesen, and E.H. Koo, *Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624)*. FASEB J, 2006. **20**(8): p. 1254-6.
150. Stoka, V., V. Turk, and D.E. Bredesen, *Differential regulation of the intrinsic pathway of apoptosis in brain and liver during ageing*. FEBS Lett, 2006. **580**(15): p. 3739-45.
151. Bredesen, D.E., *Key note lecture: toward a mechanistic taxonomy for cell death programs*. Stroke, 2007. **38**(2 Suppl): p. 652-60.
152. Bredesen, D.E. and S. Rabizadeh, *APP-based neuroprotective strategies*. Curr Alzheimer Res, 2007. **4**(5): p. 541-3.
153. Cusack, M.P., B. Thibert, D.E. Bredesen, and G. Del Rio, *Efficient identification of critical residues based only on protein structure by network analysis*. PLoS One, 2007. **2**(5): p. e421.
154. del Rio, G., D.J. Kane, K.D. Ball, and D.E. Bredesen, *A novel motif identified in dependence receptors*. PLoS One, 2007. **2**(5): p. e463.
155. Egger, L., D.T. Madden, C. Rheme, R.V. Rao, and D.E. Bredesen, *Endoplasmic reticulum stress-induced cell death mediated by the proteasome*. Cell Death Differ, 2007. **14**(6): p. 1172-80.
156. Galvan, V., S. Banwait, P. Spilman, O.F. Gorostiza, A. Peel, M. Ataie, D. Crippen, W. Huang, G. Sidhu, H. Ichijo, and D.E. Bredesen, *Interaction of ASK1 and the beta-amyloid precursor protein in a stress-signaling complex*. Neurobiol Dis, 2007. **28**(1): p. 65-75.
157. Galvan, V. and D.E. Bredesen, *Neurogenesis in the adult brain: implications for Alzheimer's disease*. CNS Neurol Disord Drug Targets, 2007. **6**(5): p. 303-10.
158. Kurakin, A. and D.E. Bredesen, *An unconventional IAP-binding motif revealed by target-assisted iterative screening (TAIS) of the BIR3-clAP1 domain*. J Mol Recognit, 2007. **20**(1): p. 39-50.
159. Kurakin, A., A. Swistowski, S.C. Wu, and D.E. Bredesen, *The PDZ domain as a complex adaptive system*. PLoS One, 2007. **2**(9): p. e953.
160. Levy, R.M., D.E. Bredesen, and M.L. Rosenblum, *Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. 1985*. J Neurosurg, 2007. **107**(6): p. 1253-73; discussion 1251.
161. Madden, D.T., L. Egger, and D.E. Bredesen, *A calpain-like protease inhibits autophagic cell death*. Autophagy, 2007. **3**(5): p. 519-22.
162. Stoka, V., V. Turk, and D.E. Bredesen, *Differential regulation of Smac/DIABLO and Hsp-70 during brain maturation*. Neuromolecular Med, 2007. **9**(3): p. 255-63.
163. Young, J.E., L. Gouw, S. Propp, B.L. Sopher, J. Taylor, A. Lin, E. Hermel, A. Logvinova, S.F. Chen, S. Chen, et al., *Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation*. J Biol Chem, 2007. **282**(41): p. 30150-60.
164. Bakhshi, J., L. Weinstein, K.S. Poksay, B. Nishinaga, D.E. Bredesen, and R.V. Rao, *Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin*. Apoptosis, 2008. **13**(7): p. 904-14.
165. Banwait, S., V. Galvan, J. Zhang, O.F. Gorostiza, M. Ataie, W. Huang, D. Crippen, E.H. Koo, and D.E. Bredesen, *C-terminal cleavage of the amyloid-beta protein precursor at Asp664: a switch associated with Alzheimer's disease*. J Alzheimers Dis, 2008. **13**(1): p. 1-16.
166. Bredesen, D.E., *Programmed cell death mechanisms in neurological disease*. Curr Mol Med, 2008. **8**(3): p. 173-86.

167. Chinta, S.J., A. Rane, K.S. Poksay, D.E. Bredesen, J.K. Andersen, and R.V. Rao, *Coupling endoplasmic reticulum stress to the cell death program in dopaminergic cells: effect of paraquat*. *Neuromolecular Med*, 2008. **10**(4): p. 333-42.
168. Ellerby, H.M., D.E. Bredesen, S. Fujimura, and V. John, *Hunter-killer peptide (HKP) for targeted therapy*. *J Med Chem*, 2008. **51**(19): p. 5887-92.
169. Galvan, V., J. Zhang, O.F. Gorostiza, S. Banwait, W. Huang, M. Ataie, H. Tang, and D.E. Bredesen, *Long-term prevention of Alzheimer's disease-like behavioral deficits in PDAPP mice carrying a mutation in Asp664*. *Behav Brain Res*, 2008. **191**(2): p. 246-55.
170. Klionsky, D.J., H. Abeliovich, P. Agostinis, D.K. Agrawal, G. Aliev, D.S. Askew, M. Baba, E.H. Baehrecke, B.A. Bahr, A. Ballabio, et al., *Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes*. *Autophagy*, 2008. **4**(2): p. 151-75.
171. Nguyen, T.V., V. Galvan, W. Huang, S. Banwait, H. Tang, J. Zhang, and D.E. Bredesen, *Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664*. *J Neurochem*, 2008. **104**(4): p. 1065-80.
172. Rossi, D., L. Brambilla, C.F. Valori, C. Roncoroni, A. Crugnola, T. Yokota, D.E. Bredesen, and A. Volterra, *Focal degeneration of astrocytes in amyotrophic lateral sclerosis*. *Cell Death Differ*, 2008. **15**(11): p. 1691-700.
173. Bredesen, D.E., *Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence*. *Mol Neurodegener*, 2009. **4**: p. 27.
174. Chinta, S.J., K.S. Poksay, G. Kaundinya, M. Hart, D.E. Bredesen, J.K. Andersen, and R.V. Rao, *Endoplasmic reticulum stress-induced cell death in dopaminergic cells: effect of resveratrol*. *J Mol Neurosci*, 2009. **39**(1-2): p. 157-68.
175. Fombonne, J., S. Rabizadeh, S. Banwait, P. Mehlen, and D.E. Bredesen, *Selective vulnerability in Alzheimer's disease: amyloid precursor protein and p75(NTR) interaction*. *Ann Neurol*, 2009. **65**(3): p. 294-303.
176. Galluzzi, L., S.A. Aaronson, J. Abrams, E.S. Alnemri, D.W. Andrews, E.H. Baehrecke, N.G. Bazan, M.V. Blagosklonny, K. Blomgren, C. Borner, et al., *Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes*. *Cell Death Differ*, 2009. **16**(8): p. 1093-107.
177. Lourenco, F.C., V. Galvan, J. Fombonne, V. Corset, F. Llambi, U. Muller, D.E. Bredesen, and P. Mehlen, *Netrin-1 interacts with amyloid precursor protein and regulates amyloid-beta production*. *Cell Death Differ*, 2009. **16**(5): p. 655-63.
178. Mille, F., F. Llambi, C. Guix, C. Delloye-Bourgeois, C. Guenebeaud, S. Castro-Obregon, D.E. Bredesen, C. Thibert, and P. Mehlen, *Interfering with multimerization of netrin-1 receptors triggers tumor cell death*. *Cell Death Differ*, 2009. **16**(10): p. 1344-51.
179. Park, S.A., G.M. Shaked, D.E. Bredesen, and E.H. Koo, *Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein*. *Biochem Biophys Res Commun*, 2009. **388**(2): p. 450-5.
180. Swistowski, A., Q. Zhang, M.E. Orcholski, D. Crippen, C. Vitelli, A. Kurakin, and D.E. Bredesen, *Novel mediators of amyloid precursor protein signaling*. *J Neurosci*, 2009. **29**(50): p. 15703-12.
181. Bredesen, D.E., V. John, and V. Galvan, *Importance of the caspase cleavage site in amyloid-beta protein precursor*. *J Alzheimers Dis*, 2010. **22**(1): p. 57-63.
182. Butterfield, D.A., V. Galvan, M.B. Lange, H. Tang, R.A. Sowell, P. Spilman, J. Fombonne, O. Gorostiza, J. Zhang, R. Sultana, and D.E. Bredesen, *In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP*. *Free Radic Biol Med*, 2010. **48**(1): p. 136-44.
183. Harris, J.A., N. Devidze, B. Halabisky, I. Lo, M.T. Thwin, G.Q. Yu, D.E. Bredesen, E. Masliah, and L. Mucke, *Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein*. *J Neurosci*, 2010. **30**(1): p. 372-81.

184. Sperandio, S., K.S. Poksay, B. Schilling, D. Crippen, B.W. Gibson, and D.E. Bredesen, *Identification of new modulators and protein alterations in non-apoptotic programmed cell death*. J Cell Biochem, 2010. **111**(6): p. 1401-12.
185. Spilman, P., N. Podlutskaya, M.J. Hart, J. Debnath, O. Gorostiza, D. Bredesen, A. Richardson, R. Strong, and V. Galvan, *Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease*. PLoS One, 2010. **5**(4): p. e9979.
186. Zhang, J., O.F. Gorostiza, H. Tang, D.E. Bredesen, and V. Galvan, *Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: a role for early experience*. Behav Brain Res, 2010. **206**(2): p. 202-7.
187. Descamps, O., Q. Zhang, V. John, and D.E. Bredesen, *Induction of the C-terminal proteolytic cleavage of AbetaPP by statins*. J Alzheimers Dis, 2011. **25**(1): p. 51-7.
188. Libeu, C.P., K.S. Poksay, V. John, and D.E. Bredesen, *Structural and functional alterations in amyloid-beta precursor protein induced by amyloid-beta peptides*. J Alzheimers Dis, 2011. **25**(3): p. 547-66.
189. Madden, D.T., D. Davila-Kruger, S. Melov, and D.E. Bredesen, *Human embryonic stem cells express elevated levels of multiple pro-apoptotic BCL-2 family members*. PLoS One, 2011. **6**(12): p. e28530.
190. Mehlen, P. and D.E. Bredesen, *Dependence receptors: from basic research to drug development*. Sci Signal, 2011. **4**(157): p. mr2.
191. Orcholski, M.E., Q. Zhang, and D.E. Bredesen, *Signaling via amyloid precursor-like proteins APLP1 and APLP2*. J Alzheimers Dis, 2011. **23**(4): p. 689-99.
192. Poksay, K.S., D.T. Madden, A.K. Peter, K. Niazi, S. Banwait, D. Crippen, D.E. Bredesen, and R.V. Rao, *Valosin-containing protein gene mutations: cellular phenotypes relevant to neurodegeneration*. J Mol Neurosci, 2011. **44**(2): p. 91-102.
193. Robinson, R.A., M.B. Lange, R. Sultana, V. Galvan, J. Fombonne, O. Gorostiza, J. Zhang, G. Warriar, J. Cai, W.M. Pierce, et al., *Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-beta peptide of amyloid precursor protein*. Neuroscience, 2011. **177**: p. 207-22.
194. Vogt, D.L., D. Thomas, V. Galvan, D.E. Bredesen, B.T. Lamb, and S.W. Pimplikar, *Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain*. Neurobiol Aging, 2011. **32**(9): p. 1725-9.
195. Zhang, J., R.V. Rao, P. Spilman, J. Mangada, L. Xie, C. Vitelli, O.F. Gorostiza, D.T. Madden, X. Zeng, K. Jin, et al., *Endogenously EGFP-Labeled Mouse Embryonic Stem Cells*. Aging Dis, 2011. **2**(1): p. 18-29.
196. Bredesen, D., *mCiRNA-synaptic crystal ball?* Aging (Albany NY), 2012. **4**(11): p. 732-3.
197. Choi, S.W., A.A. Gerencser, R. Ng, J.M. Flynn, S. Melov, S.R. Danielson, B.W. Gibson, D.G. Nicholls, D.E. Bredesen, and M.D. Brand, *No consistent bioenergetic defects in presynaptic nerve terminals isolated from mouse models of Alzheimer's disease*. J Neurosci, 2012. **32**(47): p. 16775-84.
198. Libeu, C.A., O. Descamps, Q. Zhang, V. John, and D.E. Bredesen, *Altering APP proteolysis: increasing sAPPalpha production by targeting dimerization of the APP ectodomain*. PLoS One, 2012. **7**(6): p. e40027.
199. Poksay, K.S., S. Banwait, D. Crippen, X. Mao, D.E. Bredesen, and R.V. Rao, *The small chaperone protein p23 and its cleaved product p19 in cellular stress*. J Mol Neurosci, 2012. **46**(2): p. 303-14.
200. Rao, R.V., O. Descamps, V. John, and D.E. Bredesen, *Ayurvedic medicinal plants for Alzheimer's disease: a review*. Alzheimers Res Ther, 2012. **4**(3): p. 22.
201. Rodriguez Plaza, J.G., A. Villalon Rojas, S. Herrera, G. Garza-Ramos, A. Torres Larios, C. Amero, G. Zarraga Granados, M. Gutierrez Aguilar, M.T. Lara Ortiz, C. Polanco Gonzalez, et al., *Moonlighting peptides with emerging function*. PLoS One, 2012. **7**(7): p. e40125.

202. Sultana, R., R.A. Robinson, M.B. Lange, A. Fiorini, V. Galvan, J. Fombonne, A. Baker, O. Gorostiza, J. Zhang, J. Cai, et al., *Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 in Alzheimer disease pathogenesis?* Antioxid Redox Signal, 2012. **17**(11): p. 1507-14.
203. Bredesen, D.E. and V. John, *Next generation therapeutics for Alzheimer's disease.* EMBO Mol Med, 2013. **5**(6): p. 795-8.
204. Descamps, O., P. Spilman, Q. Zhang, C.P. Libeu, K. Poksay, O. Gorostiza, J. Campagna, B. Jagodzinska, D.E. Bredesen, and V. John, *AbetaPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease.* J Alzheimers Dis, 2013. **37**(2): p. 343-55.
205. Theendakara, V., A. Patent, C.A. Peters Libeu, B. Philpot, S. Flores, O. Descamps, K.S. Poksay, Q. Zhang, G. Cailing, M. Hart, et al., *Neuroprotective Sirtuin ratio reversed by ApoE4.* Proc Natl Acad Sci U S A, 2013. **110**(45): p. 18303-8.
206. Zhang, J., P. Spilman, S. Chen, O. Gorostiza, A. Matalis, K. Niazi, D.E. Bredesen, and R.V. Rao, *The small co-chaperone p23 overexpressing transgenic mouse.* J Neurosci Methods, 2013. **212**(2): p. 190-4.
207. Bredesen, D.E., *Reversal of cognitive decline: a novel therapeutic program.* Aging (Albany NY), 2014. **6**(9): p. 707-17.
208. Spilman, P., O. Descamps, O. Gorostiza, C. Peters-Libeu, K.S. Poksay, A. Matalis, J. Campagna, A. Patent, R. Rao, V. John, and D.E. Bredesen, *The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.* Brain Res, 2014. **1551**: p. 25-44.
209. Zhang, Q., O. Descamps, M.J. Hart, K.S. Poksay, P. Spilman, D.J. Kane, O. Gorostiza, V. John, and D.E. Bredesen, *Paradoxical effect of TrkA inhibition in Alzheimer's disease models.* J Alzheimers Dis, 2014. **40**(3): p. 605-617.
210. Bredesen, D.E., *Metabolic profiling distinguishes three subtypes of Alzheimer's disease.* Aging (Albany NY), 2015. **7**(8): p. 595-600.
211. Ellerby, H.M., D.E. Bredesen, S. Fujimura, and V. John, *Correction to hunter-killer peptide (HKP) for targeted therapy.* J Med Chem, 2015. **58**(4): p. 2045.
212. Fiala, M., R.C. Halder, B. Sagong, O. Ross, J. Sayre, V. Porter, and D.E. Bredesen, *omega-3 Supplementation increases amyloid-beta phagocytosis and resolvin D1 in patients with minor cognitive impairment.* FASEB J, 2015. **29**(7): p. 2681-9.
213. Galluzzi, L., J.M. Bravo-San Pedro, I. Vitale, S.A. Aaronson, J.M. Abrams, D. Adam, E.S. Alnemri, L. Altucci, D. Andrews, M. Annicchiarico-Petruzzelli, et al., *Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.* Cell Death Differ, 2015. **22**(1): p. 58-73.
214. Kurakin, A. and D.E. Bredesen, *Dynamic self-guiding analysis of Alzheimer's disease.* Oncotarget, 2015. **6**(16): p. 14092-122.
215. Peters-Libeu, C., J. Campagna, M. Mitsumori, K.S. Poksay, P. Spilman, A. Sabogal, D.E. Bredesen, and V. John, *sAbetaPPalpha is a Potent Endogenous Inhibitor of BACE1.* J Alzheimers Dis, 2015. **47**(3): p. 545-55.
216. Raji, C.A., H. Eyre, S.H. Wei, D.E. Bredesen, S. Moylan, M. Law, G. Small, P.M. Thompson, R.M. Friedlander, D.H. Silverman, et al., *Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline.* AJNR Am J Neuroradiol, 2015. **36**(10): p. 1803-9.
217. Zhang, Q., G. Du, V. John, P. Kapahi, and D.E. Bredesen, *Alzheimer's Model Develops Early ADHD Syndrome.* J Neurol Neurophysiol, 2015. **6**(6): p. 1-6.
218. Bredesen, D.E., E.C. Amos, J. Canick, M. Ackerley, C. Raji, M. Fiala, and J. Ahdidan, *Reversal of cognitive decline in Alzheimer's disease.* Aging (Albany NY), 2016. **8**(6): p. 1250-8.
219. Spilman, P.R., V. Corset, O. Gorostiza, K.S. Poksay, V. Galvan, J. Zhang, R. Rao, C. Peters-Libeu, J. Vincelette, A. McGeehan, et al., *Netrin-1 Interrupts Amyloid-beta Amplification, Increases*

- sAbetaPPalpha in vitro and in vivo, and Improves Cognition in a Mouse Model of Alzheimer's Disease.* J Alzheimers Dis, 2016. **52**(1): p. 223-42.
220. Theendakara, V., C.A. Peters-Libeu, P. Spilman, K.S. Poksay, D.E. Bredesen, and R.V. Rao, *Direct Transcriptional Effects of Apolipoprotein E.* J Neurosci, 2016. **36**(3): p. 685-700.
221. Bredesen, D.E. and R.V. Rao, *Ayurvedic Profiling of Alzheimer's Disease.* Altern Ther Health Med, 2017. **23**(3): p. 46-50.
222. Famenini, S., E.A. Rigali, H.M. Olivera-Perez, J. Dang, M.T. Chang, R. Halder, R.V. Rao, M. Pellegrini, V. Porter, D. Bredesen, and M. Fiala, *Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on omega-3 supplementation.* FASEB J, 2017. **31**(1): p. 148-160.
223. Poksay, K.S., D.J. Sheffler, P. Spilman, J. Campagna, B. Jagodzinska, O. Descamps, O. Gorostiza, A. Matalis, M. Mullenix, D.E. Bredesen, et al., *Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production.* Front Pharmacol, 2017. **8**: p. 46.
224. Theendakara, V., D.E. Bredesen, and R.V. Rao, *Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease.* Mol Cell Neurosci, 2017. **83**: p. 83-91.
225. Campagna, J., P. Spilman, B. Jagodzinska, D. Bai, A. Hatami, C. Zhu, T. Bilousova, M. Jun, C.J. Elias, J. Pham, et al., *A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model.* Sci Rep, 2018. **8**(1): p. 17574.
226. Theendakara, V., C.A. Peters-Libeu, D.E. Bredesen, and R.V. Rao, *Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease.* Mol Neurobiol, 2018. **55**(6): p. 5243-5254.
227. Kurakin, A. and D.E. Bredesen, *Alzheimer's disease as a systems network disorder: chronic stress/dyshomeostasis, innate immunity, and genetics.* Aging (Albany NY), 2020. **12**(18): p. 17815-17844.
228. Gregory, J., Y.V. Vengalasetti, D.E. Bredesen, and R.V. Rao, *Neuroprotective Herbs for the Management of Alzheimer's Disease.* Biomolecules, 2021. **11**(4).
229. Palmsten, K., D. Bredesen, M.M. JaKa, P.C. Kumar, J.Y. Ziegenfuss, and E.O. Kharbanda, *"I know my body better than you:" patient focus groups to inform a decision aid on oral corticosteroid use during pregnancy.* Pharmacoepidemiol Drug Saf, 2021. **30**(4): p. 451-461.
230. Ross, M.K., C. Raji, K.L. Lokken, D.E. Bredesen, J.C. Roach, C.C. Funk, N. Price, N. Rappaport, L. Hood, and J.R. Heath, *Case Study: A Precision Medicine Approach to Multifactorial Dementia and Alzheimer's Disease.* J Alzheimers Dis Parkinsonism, 2021. **11**(Suppl 5).
231. Johnson, R.J., D.R. Tolan, D. Bredesen, M. Nagel, L.G. Sanchez-Lozada, M. Fini, S. Burtis, M.A. Lanaspá, and D. Perlmutter, *Could Alzheimer's disease be a maladaptation of an evolutionary survival pathway mediated by intracerebral fructose and uric acid metabolism?* Am J Clin Nutr, 2023. **117**(3): p. 455-466.
232. Rao, R.V., K.G. Subramaniam, J. Gregory, A.L. Bredesen, C. Coward, S. Okada, L. Kelly, and D.E. Bredesen, *Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer's Disease and MCI: A Review.* Int J Mol Sci, 2023. **24**(2).